A Fatal Breakthrough COVID-19 Case with prolonged high viral load

An Asian man in his 70s developed a fever at home 11 days after his second dose of the mRNA vaccine BNT162b2 (disease day 0). On disease day 10, he was admitted to the hospital following to his worsened status. On arrival, his oxygen saturation was 56% while he was breathing ambient air. Remdesivir, methylprednisolone treatment was initiated along with a single dose of 8 mg/kg tocilizumab. He required a noninvasive, positive-pressure ventilator for hypoxemia. On disease day 19, his oxygen level abruptly dropped, and intubation was needed. On disease day 26, soon after extubation, he developed pneumothorax and acute respiratory distress syndrome. High SARS-CoV-2 viral load (Delta variant, although several mix alleles were found in the specimens collected on disease days 27-29) was observed until 1 month after onset. He died on disease day 31. 


One year before admission he successfully received six courses of bendamustine-rituximab (BR) therapy for stage 3 mucosa-associated lymphoid tissue (MALT) lymphoma with no evidence of relapse since then. 

The authors of this report attribute this fatal case to four causes: (i) impaired responsiveness toward SARS-CoV-2 vaccine, (ii) prolonged high SARS-CoV-2 viral load, (iii) difficulties in controlling T-cell immunodeficiency and cytokine storm, and (iv) the possibility of bacterial superinfection. 


REFERENCE

Kamegai K, Iwamoto N, Togano T, Maeda K, Takamatsu Y, Miyazato Y, Ishikane M, Mizokami M, Sugiyama M, Iida S, Miyamoto S. A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy. International Journal of Infectious Diseases. 2022 Aug 1;121:85-8.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis ...
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an incr...
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high ...
Read more